Login
Companies $BHVN
$13.80 +$0.00 (0.0%) After hours
Biohaven Ltd. logo

Biohaven Ltd.

biohaven.com

What Do They Do?

Develops potential medicines for people with epilepsy, immune diseases, and neuromuscular and metabolic conditions.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +25% (Loss)
vs −$173.4M in Q3 FY2025
  • Oct 8, 2026 Biohaven licensed its MoDE degrader portfolio to Ono in select Asian markets Ono will pay $80 million upfront, a possible $20 million milestone, and royalties of approximately 20% on licensed sales.
  • Aug 26, 2026 Biohaven licensed its Kv7 platform, including opakalim, to SK Biopharmaceuticals The agreement includes a $400 million upfront fee and up to $150 million in development and regulatory milestone payments.

Narrower clinical focus The older report described a broad pipeline centered on neurological and neuropsychiatric diseases, with programs spanning multiple platforms. The latest report describes a narrower focus on epilepsy, protein-degrader treatments for immune diseases, and treatments for neuromuscular and metabolic diseases.

Who Do They Compete With?

Competes with Glenmark

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support